Phase III Scorpio-PEP study results showed Shionogi & Co. Ltd.’s oral antiviral ensitrelvir fumaric acid (Xocova) reduced risk of symptomatic COVID-19 infection in subjects who were exposed to the virus by infected household members.
Isoniazid is a first-line medicine for tuberculosis (TB) treatment. It is a prodrug activated by the mycobacterial catalase-peroxidase enzyme KatG. However, the development of isoniazid resistance compromises treatment efficacy and contributes to multidrug-resistant TB infections.
One of the challenges associated with COVID-19 has been an increase of secondary infections, including fungal infections. These coinfections can hinder treatment efficacy and increase illness severity.
Researchers from Purdue University and Eradivir Inc. presented a newly developed bispecific small molecule (zanDR) that bound and inhibited influenza neuraminidase on both free virus and virus-infected cells and also recruited the immune system. zanDR recruited naturally occurring anti-rhamnose and anti-dinitrophenyl (DNP) antibodies with rhamnose and DNP haptens.
Scientists at Centre Hospitalier Regional Universitaire de Lille, Centre National de la Recherche Scientifique, Institut National De La Santé et de la Recherche Médicale, Institut Pasteur de Lille and Université de Lille have patented conjugates comprising siderophore moieties covalently linked to cargo moieties through a linker reported to be useful for the diagnosis and treatment of bacterial infections.
Previous reports have disclosed the development of Shigella conjugate vaccines (SCVs) using a platform squaric acid chemistry conjugation approach and carrier protein recombinant fragment of tetanus toxin heavy chain (rTTHc).
Researchers from Universidad Carlos III de Madrid presented the development and preclinical characterization of a novel specific radiotracer for the diagnosis of Clostridioides difficile infection (CDI).
With the U.S. FDA’s approval of Orlynvah (sulopenem etzadroxil and probenecid) for uncomplicated urinary tract infections, Iterum Therapeutics plc can move on from regulatory delays and prepare to launch only the second FDA-approved treatment for the indication in the past 20 years.
Siga Technologies Inc. has entered into an agreement with Vanderbilt University to obtain a license to a portfolio of preclinical fully human monoclonal antibodies (MAbs) which could be used as potential treatments for a broad range of orthopoxviruses, including smallpox and mpox.
Studies evaluating the in vitro and in vivo antifungal activity, hemolytic activity and cytotoxicity of COT-832, a novel polyene macrolide antifungal that is a chemical modification of amphotericin B (AmB), were presented at IDWeek by Shionogi & Co. Ltd.
RSS
